Autolus, a clinical-stage biopharmaceutical company, specializes in advancing next-generation, programmed T cell therapies to combat cancer. Employing an array of proprietary and modular T cell programming technologies, the company is dedicated to crafting precisely targeted, controlled, and highly active T cell therapies. These therapies are intricately designed to enhance the recognition of cancer cells, dismantle their defense mechanisms, and effectively eliminate these cells. Autolus boasts a robust pipeline of product candidates under development, focusing on addressing hematological malignancies and solid tumors.

Reprogramming T Cell Product Candidates Using Cell Programming Technologies and CARs

In the realm of cancer treatment, where surgery, chemotherapy, and radiation therapy have long been the standard, a new frontier has emerged – cancer immunotherapy. This innovative approach leverages the inherent power of a patient's immune system to combat the disease effectively.

At the forefront of this immunotherapeutic revolution is Autolus, a pioneering clinical-stage biopharmaceutical company dedicated to developing next-generation programmed T cell therapies for cancer treatment. T cells, a type of white blood cell integral to the immune system's defense mechanism, play a crucial role in detecting and eliminating abnormal or cancerous cells. However, certain cancer cells can evade detection, leading to the development of tumors.

To address this challenge, Autolus is employing advanced cell programming technologies and specialized manufacturing processes to create precisely targeted, controlled, and highly active T cell therapies. These innovative therapies are designed to enhance the recognition of cancer cells, dismantle their defense mechanisms, and eliminate them effectively.

Autolus employs Chimeric Antigen Receptors (CARs) as a key element in reprogramming their T cell product candidates. These receptors amalgamate the tumor recognition domain of an antibody with the activation and costimulatory domains from the T cell receptor. This strategic combination rearms a patient's T cells, empowering them to recognize and eradicate cancer cells more effectively. Autolus's groundbreaking approach holds promise for advancing the field of cancer immunotherapy and revolutionizing the landscape of cancer treatment.

Programmed T Cell Therapies in the Treatment of Hematological Malignancies and Solid Tumors

In the dynamic landscape of cancer therapeutics, Autolus, a pioneering biopharmaceutical company, is at the forefront of developing next-generation, programmed T cell therapies. These innovative therapies are tailored to address hematological malignancies and solid tumors, representing a paradigm shift in cancer treatment approaches.

The company's lead therapeutic candidate, obe-cel, has demonstrated promising outcomes, meeting its primary endpoint at an interim analysis of the pivotal phase 2 FELIX study for adult Acute Lymphoblastic Leukemia (ALL). Autolus presented additional data at prestigious medical conferences, including ASCO and EHA in June 2023, showcasing the positive impact of obe-cel. Further insights, including longer-term follow-up data and subgroup analysis, were unveiled at ASH in December 2023. The company aims to share more significant findings at upcoming medical conferences in the first half of 2024. In November 2023, Autolus submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for obe-cel.

The therapeutic potential of obe-cel extends beyond adult ALL, as ongoing clinical studies explore its efficacy in B-Non-Hodgkin's Lymphoma (NHL) indications and pediatric ALL. Autolus is concurrently advancing a robust pipeline of assets, spanning both preclinical and clinical development stages, targeting a spectrum of hematological malignancies and solid tumors. Autolus's commitment to innovation and groundbreaking therapies signifies a significant stride in reshaping the landscape of cancer treatment.Top of Form

Dr. Christian Itin | Chief Executive Officer

Dr. Christian Itin joined Autolus as Chairman of the Board of Directors at the inception of the company and subsequently also took on the role of Chief Executive Officer. In April 2021, a new Chairman was appointed with Christian remaining as Chief Executive Officer.

Previously he was Chief Executive Officer and Chairman of the Board of Directors of Cytos Biotechnology Ltd, a public biotechnology company that merged with Kuros Biosurgery Holding Ltd, and until May 2019 he served as Chairman of the Board of Directors of the merged entity, renamed Kuros Biosciences Ltd.

Prior to joining Cytos, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company which was acquired in March 2012 by Amgen, Inc. for USD 1.2 billion in cash. Micromet pioneered T-cell engaging antibodies and with blinatumomab developed the first approved product in this field.

After serving in senior management roles at Micromet, Christian was appointed Chief Executive Officer in 2004. Prior to joining Micromet in 1999, Christian co-founded Zyomyx, Inc., a protein chip company based in Hayward, CA, USA.

He received a diploma in biology and a PhD in cell biology from the University of Basel, Switzerland. In addition, he also performed post-doctoral research at the Biocenter of Basel University and at Stanford University School of Medicine, CA, USA.

“Our dedication to innovation underscores a profound mission – advancing science to conquer cancer and offering renewed hope to patients worldwide.”